相关实验视频

Updated: May 29, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

针对HER2向单克隆抗体的细胞保护性自的证据

Ahmed M Elshazly¹, Aya A Elzahed², David A Gewirtz³

¹Department of Pharmacology and Toxicology, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.

The Journal of pharmacology and experimental therapeutics

|February 1, 2025

概括

自在对HER2向疗法 (如特拉斯图祖马布) 的耐药性方面发挥着作用. 调节自可能会提高对HER2阳性癌症的治疗效率.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞生物学细胞生物学

背景情况:

针对HER2的单克隆抗体 (例如,trastuzumab) 改善了HER2阳性乳腺癌和胃癌的结果.
治疗耐药性限制了这些向药物的临床疗效.
自是一种细胞降解过程,涉及到对各种癌症疗法的耐药性.

研究的目的:

审查由HER2向单克隆抗体诱导的自机制.
探索向或调节自的潜力,以克服对HER2向疗法的抗性.
评估自调节作为辅助策略的临床可转化性.

主要方法:

对调查对HER2向疗法的自反应的研究的文献综述.
对参与自诱导的分子机制和信号通路的分析.
专注于在HER2过度表达的癌症中使用trastuzumab和trastuzumab-emtansine.

主要成果:

自因应HER2向单克隆抗体而被诱导.
细胞保护性和非保护性形式的自可以被触发.
自在抵抗中的作用是复杂的,并且取决于环境.

结论:

自调节是一种潜在的策略,可以提高针对HER2的疗法的疗效.
向自可能有助于克服对trastuzumab和相关药物的耐药性.
需要进一步的临床研究来验证自调节作为辅助癌症治疗.

关键词:

自自是一种自的过程.细胞保护性细胞保护性在HER2中,HER2是HER2.这就是Trastuzumab.特拉斯图祖马布-埃姆坦辛的使用情况

更多相关视频

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Autophagy

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...